HealthCapital Newsletter March 2019
HealthCapital Newsletter March 2019 If this newsletter is not displayed properly, please click here. Land Brandenburg und be Berlin
load images
healthCApital Newsletter March 2019
load images

Dear Sir or Madam,

The capital region has had a good start to 2019. In the race for billions in EU funding as a Future & Emerging Technologies (FET) Flagship, only two health-related projects made it into the group of six finalists. Both are being coordinated in Berlin and seek to develop highly innovative treatment methods.

The region's excellence in developing new therapeutic approaches is also evident in the work being done here in advanced therapy medicinal products (ATMP). In the article on the Berlin Center for Advanced Therapies (BeCAT), you can read about how the infrastructure for innovative drug research is being expanded to establish the basis for developing the treatment concepts of the future.

The best way to find out about these and many other innovative projects is in person. From April 9 to 11, 2019, the DMEA will be offering the ideal platform for an exchange of information related to digital health.

Another yearly highlight in spring is the BIONNALE (May 7, 2019), which brings together stakeholders across the life sciences for numerous opportunities for specialist exchange and networking. We look forward to welcoming you here in Berlin!



load images

State-of-the-art pharmaceutical research at BeCAT

The Berlin Center for Advanced Therapies (BeCAT) is researching innovative therapy and production approaches using cell-based drugs (ATMPs). Novel treatment concepts will thus find their way into everyday clinical life more quickly and patients’ chances of recovery will be increased.



Business News


CRISPR Therapeutics and ProBioGen Sign Collaboration and License Agreement to Develop Novel In Vivo Delivery Technologies

CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and ProBioGen, a premier German service and technology provider, today announced a multi-year research collaboration focused on the development of novel in vivo delivery modalities for CRISPR/Cas9 leveraging ProBioGen’s existing technology and expertise.



Boehringer Ingelheim and 3B Pharmaceuticals sign drug discovery collaboration

Harnessing the structural plethora of peptides to discover novel therapeutics.
3B Pharmaceuticals GmbH (3BP), a private German biotechnology company today announced a multi-year collaboration in the field of peptide-led drug discovery with Boehringer Ingelheim.



NOXXON announces key findings that NOX-A12 plus Keytruda® induces an immune response and results in clinical benefit for patients

Findings include stable disease and prolonged time on treatment vs. prior therapy in heavily pretreated metastatic pancreatic and colorectal cancer patients



Bayer’s darolutamide plus androgen deprivation therapy (ADT) significantly extends metastasis-free survival with a favorable safety profile compared to placebo plus ADT in non-metastatic castration-resistant prostate cancer

» more

Adrenomed AG announces publication of Phase II trial design of Adrecizumab to treat septic shock

» mehr

Financing for Telemedicine Startup Kinderheldin

» more

ProBioGen’s GlymaxX® ADCC Enhancement Technology used by Betta Pharmaceuticals

» more

Science and Technology News


Restore Health – Therapies that cure

Shifting from treating symptoms to curing diseases and making Europe the world leader in Advanced Therapies is the aspiration of RESTORE – the Large-Scale Research Initiative, led by Charité. On February 8, the European Commission (EC) backed that vision and announced that RESTORE will receive initial funding of EUR 1m and invited the consortium to fully develop their concept and to further expand the community that strives to propel Europe to the forefront in Advanced Therapies.



Europe looks to cells for a healthier future

Our body’s cells are constantly changing. But which of these changes are healthy developments and which lead to serious diseases? This is what LifeTime, a new transnational and interdisciplinary initiative of leading European researchers, aims to discover. The consortium is jointly coordinated by the Max Delbrück Center in Berlin and the Institut Curie in Paris, with the Helmholtz Association and the CNRS. It has now cleared an important hurdle: LifeTime will be given one million euros and one year to develop a plan to embed its vision for a healthier future within the European research and innovation landscape.

Red more...


Charité leads on three new EU-funded projects

Researchers from Charité – Universitätsmedizin Berlin have successfully convinced the EU Commission of the quality of their research proposals. As a result, the EU’s Horizon 2020 research and innovation program will provide funding for a total of nine collaborative research projects, three of which will be led by Charité. For its involvement in all nine of these projects, Charité will receive more than €10 million in funding.

Red more...


Angela Merkel opened the new MDC research building for the Berlin Institute for Molecular Systems Biology

» more

NTU Singapore and Max Planck Institute of Colloids and Interfaces launch joint lab in healthcare and robotics

» more

John P. A. Ioannidis will become Einstein BIH Visiting Fellow and start a research group at the QUEST Center of the BIH

» more

Berlin universities and the University of Oxford consolidate their cooperation

» more

Tracking development cell by cell is ‘Breakthrough of the Year’ – Berlin-based MDC is a hot spot for such research

» more

Scientists decipher protein structure after more than fifty years of research

» more

Researchers decipher one of the body’s brain regeneration mechanisms

» more

Technology and Cooperation Offers


Blood transfusion safety system Cairos

» more

Berlin university offers licencing or research partnership for development of a microstructured polymer stent

» more

CortBS- Ultrasound Osteoporosis Dx

» more

For more news from the cluster healthcare industries click here.



01. - 05.04.2019

Berlin Partner Participates in the 6th Annual Health Innovation Week in Toronto

» more
09. - 11.04.2019

DMEA - Connecting Digital Health

» more


» more
16. - 17.05.2019

4th "NanoBio Surfaces and Interfaces in Healthcare and Science Workshop"

» more

15th Current Topics in Bioinformatics: „Can we predict outcome?“

» more
10. - 12.10.2019

XPOMET© Medicinale

» more
27. - 29.10.2019

World Health Summit 2019

» more
01. - 03.12.2019

IMTJ Medical Travel Summit 2019

» more

For more events in the life science region Berlin-Brandenburg click here.


The operator and party responsible for content in compliance with § 5 of the German Teleservices Act (TaMG) and in the meaning of the German Press Act:

Berlin Partner for Business and Technology GmbH
Fasanenstraße 85 | 10623 Berlin, Germany
Telephone: +49 30 46302-500
E-Mail: info (at)

Commercial Registry Entry
Entered in the commercial registry of the Charlottenburg District Court,
Registration number: HRB 13072 B
VAT ID: DE 136629780

Dr. Stefan Franzke

Chairman of the Supervisory Board:
Dr. Jürgen Allerkamp 

© 2019 Berlin Partner für Wirtschaft und Technologie GmbH

Unsubscribe from the newsletter
The newsletter of the Cluster healthcare industries Berlin-Brandenburg is a project of Berlin Partner for Business and Technology. Funded by the federal state of Berlin and the European Regional Development fund through the Investitionsbank Berlin.

load images load images
load images